In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal

Executive Summary

Mylan President Heather Bresch is drawing attention to the economic implications of not inspecting overseas drug manufacturing facilities as she seeks congressional support for generic user fees to finance such activities.

Related Content

Mylan's Manufacturing Maelstrom: Trans-Atlantic Recalls And Personal Citation By Gottlieb
Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
GDUFA II: Inspection Information Takes Center Stage
GDUFA Facility Self-Identification Pace Slow As Deadline Neared
Generic User Fees: FDA Reaches Out To More Trade Groups; Plan Could Mix Inspection and Application Fees
Manchin To HELP, For Now
User Fees Could Be Tough Sell On Capitol Hill
Drug Shipments Into U.S. Could Depend On Facility Inspection; FDA Mulls Import Alerts
GDUFA Timetable Unclear, But Negotiations Will Begin With Lots Of Agreement - Except For Mylan





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts